Sample Submission Guidelines
Choose the Right Starting Route for Your Model
The most useful organoid is the one that fits the biological question, available material, and intended readout. A tissue-derived epithelial model, an iPSC-derived developmental model, and an expanded existing line may all be called organoids, but they are not interchangeable. We therefore begin by defining what the model must represent and what evidence will be required before it enters the next experiment.
| Starting route | Best considered when | Important planning questions | Not automatically suitable for |
|---|---|---|---|
| Primary or tumor tissue | Donor- or tissue-linked epithelial features are central to the study | Tissue origin, collection context, viability, paired material, contamination risk, and intended passage window | Reconstructing every stromal, immune, vascular, or systemic feature of the source tissue |
| Pluripotent stem cells | Development, lineage specification, inherited variants, or engineered isogenic comparisons are central | Cell-line quality, differentiation route, maturation stage, clone effects, and batch structure | Assuming mature adult tissue function without model-specific evidence |
| Animal tissue | Species-specific biology, comparative studies, or controlled experimental material is required | Species, strain, tissue region, collection conditions, and cross-species interpretation | Direct substitution for human biology |
| Existing organoid line | A model already exists but expansion, banking, modification, or sequencing preparation is needed | Provenance, passage history, medium, matrix, recovery status, prior QC, and use restrictions | Treating incomplete records as equivalent to a newly documented line |
This avoids building a culture that cannot answer the planned question. If the requested route does not match the available material, we define an alternative or narrow the scope before work begins.
Organoid Models We Can Plan Around Your Research
Our organoid model development services are organized around model purpose rather than a fixed public catalog. Feasibility depends on source material, tissue biology, required culture format, and the downstream experiment. The following routes can be evaluated as part of a customized research plan.
Tissue-Derived and Tumor Organoid Models
Eligible normal, diseased, or tumor tissue may be used to establish cultures that retain selected source-associated features. Paired tumor and adjacent non-tumor material can be considered when available. The model is described by its source and measured characteristics—not assumed to reproduce the complete tissue microenvironment.
Inflammatory and Other Disease-Context Models
Models can examine a defined in vitro disease context, such as inflammatory stimulation or a source-associated phenotype. The disease label alone is not an acceptance criterion; we agree which measured features make the model informative.
iPSC-Derived Organoid Models
iPSC-derived organoids can support developmental, lineage, and genotype-controlled studies. Their value depends on starting cell quality, differentiation stage, cell composition, and reproducibility across differentiations. When editing is included, our iPSC gene editing and quality control capabilities can help plan confirmation and comparison of edited and control lines. The editing and clone strategy remain project-specific.
Animal-Derived and Genetically Modified Models
Animal tissue-derived and genetically modified organoids may support controlled mechanism studies. Genetic modification is not one standard package: delivery, clonal selection, confirmation, and effects on growth can change the design. Complex multi-lineage constructs remain feasibility projects.
From Establishment to Expansion and Banking
A model-development project should produce a traceable line or batch with enough information for repeat use and downstream analysis. We coordinate the following stages within the agreed scope.
- Project definition. Specify the biological comparison, source material, model route, control strategy, planned readouts, and desired delivery form.
- Material and record review. Confirm available metadata, permissions, collection conditions, passage history, or stem-cell quality information before acceptance.
- Model establishment or recovery. Initiate the selected culture route or recover an existing line under project-defined conditions.
- Expansion and monitoring. Record culture milestones, passage events, morphology, growth behavior, and deviations relevant to interpretation.
- Banking and recovery planning. Define a practical freezing point, retain identifiers across aliquots, and confirm what recovery evidence is needed.
- Fit-for-purpose assessment. Apply the agreed checks before allocating material to sequencing or functional experiments.
- Delivery and handoff. Provide the confirmed model format, culture records, quality results, and downstream sample map.
Media, matrix, passage window, scale, storage, shipping, and timelines are documented after source material and model requirements are reviewed.
Define Model Acceptance Before Culture Begins
There is no single test that proves an organoid is suitable for every use. Morphology can indicate growth or organization, but it cannot by itself establish lineage composition, genetic identity, or function. Conversely, a genomic match does not establish that a model has the required cell states or experimental response. We therefore define an evidence set that is proportional to the intended application.
| Acceptance dimension | Example evidence | What it helps determine | Key limitation |
|---|---|---|---|
| Culture status | Representative bright-field images, growth observations, passage and recovery records | Whether the culture reaches agreed operational milestones | Appearance alone does not prove biological fidelity |
| Identity and traceability | Sample identifiers, provenance, SNP/STR or other appropriate identity checks | Whether material remains linked to the intended source or line | Identity does not establish phenotype or function |
| Lineage and structure | H&E, immunostaining, qPCR, or other model-appropriate markers | Whether selected structural or lineage features are present | Marker panels address selected features, not the whole tissue |
| Genetic features | Targeted testing, whole exome sequencing, or another agreed DNA method | Whether selected variants or coding-region patterns are retained | The tested region and detection method define the conclusion |
| Expression and cell composition | mRNA sequencing, single-cell profiling, or focused expression assays | Whether expected programs or cell populations are represented | Results can be affected by passage, maturation, batch, and sample preparation |
| Functional readiness | Assay-specific pilot, recovery check, or response control | Whether the model can enter the planned downstream experiment | Readiness for one assay does not validate every application |
Acceptance criteria are agreed before culture begins whenever possible. This makes a “successful model” a research-specific decision rather than a vague promise. It also establishes what happens if a model grows but does not meet the biological criteria needed for the planned study.
Control Passage, Batch, and Model History
Organoid variability is not only donor variability. Published studies show that differentiation batch, maturation state, passage, culture reagents, matrix conditions, and cell composition can influence measured outcomes. A strong design records these factors and separates them from the biological comparison.
For tissue-derived projects, we preserve the relationship between source tissue, line, passage, treatment, and assay aliquot. For iPSC-derived projects, we consider clones, independent differentiations, relevant controls, and concurrent comparisons. Multiple assays are allocated from defined culture points.
This makes variation visible enough to inform replication, grouping, and interpretation; it does not eliminate variation.
Prepare the Model for Sequencing and Functional Studies
Model development and sequencing should not be planned separately. Bulk RNA, single-cell or single-nucleus analysis, spatial work, DNA testing, histology, and functional assays may require different handling. Late decisions can leave insufficient or incompatible material.
We connect the model plan to the appropriate organoid sequencing services and define which culture batch, passage, condition, and replicate supplies each readout. Key decisions include whether matched source tissue is retained, whether live cells or nuclei are required, whether fixed sections must preserve structure, and whether RNA/DNA extraction should occur before shipping. When the broader study includes several service areas, the parent organoid research and sequencing solution provides the project-level framework.
| Planned readout | Preserve during model development | Confirm before allocation |
|---|---|---|
| Bulk RNA profiling | Defined condition, passage, biological replicate, collection time, and RNA-compatible handling | Comparison groups, extraction route, RNA quality assessment, and analysis outputs |
| Single-cell or single-nucleus profiling | Viable-cell or nuclei route, dissociation feasibility, batch labels, and representative material | Cell/nucleus preparation, enrichment, expected composition, and method-specific QC |
| Spatial or histology analysis | Orientation, embedding/fixation route, sectioning plan, and matched morphology | Platform compatibility, region of interest, section quality, and image/data outputs |
| DNA or exome analysis | Source linkage, matched normal or baseline material where relevant, and passage identity | Comparison design, assay scope, variant outputs, and interpretation limits |
| Functional assay | Assay-ready format, recovery, plate design, controls, and treatment schedule | Endpoint, dynamic range, replicates, and how samples connect to molecular profiling |
What You Receive
Deliverables are defined by the selected route and the evidence needed for the next experiment. A project may include living or cryopreserved organoid material, culture and passage records, representative images, recovery observations, model-specific identity or marker results, and a summary of the agreed acceptance decision. If sequencing is included, sample identifiers and experimental conditions remain linked to the corresponding data and reports.
Before work starts, we clarify material ownership, permitted research use, storage, and unused material handling. File formats, aliquot numbers, shipment conditions, and analysis modules are confirmed in the project scope.
Illustrative Results from an Organoid Model Project
These illustrative result types show how model development can be documented; they are not customer data or guaranteed performance.
Culture Growth and Passage History
A time-ordered image panel can show establishment, expansion, passage, and recovery milestones while keeping each culture linked to its source and batch. This supports operational review and helps identify when a later molecular difference may coincide with a culture change.
Lineage and Structural Assessment
Selected morphology and marker panels can test whether the model retains features that matter for the research question. The appropriate panel depends on the organoid type and planned application; a generic marker set is not substituted for model-specific acceptance criteria.
Molecular Comparison with Source or Control Material
DNA or RNA profiles can compare selected molecular features across source tissue, organoid passages, edited and control lines, or experimental batches. These comparisons strengthen model documentation while remaining limited to the assay and samples actually tested.
Organoid Model Development FAQs
Can you guarantee that every submitted tissue sample will form an organoid line?
No. Establishment depends on tissue biology, collection and transport history, viable starting material, contamination, culture compatibility, and the acceptance criteria for the intended study. Feasibility and a fallback plan are discussed before work begins; we do not publish a universal success guarantee.
Can I send an existing organoid line for expansion or banking?
Potentially. We first review provenance, current format, passage history, medium and matrix information, recovery status, contamination testing, prior QC, and any use restrictions. A pilot recovery or adaptation step may be needed before scale-up.
Which model is better: tissue-derived or iPSC-derived?
Neither is universally better. Tissue-derived organoids can retain selected source-associated epithelial features, while iPSC-derived organoids can support developmental and genotype-controlled designs. The choice depends on the research question, available controls, maturity required, and downstream readout.
What quality checks are included?
Quality assessment is selected for the model and its intended use. It may combine culture records, morphology, identity, lineage markers, genetic profiling, expression analysis, recovery, or an assay-specific pilot. The final set is specified before the project starts.
How should biological replicates be defined?
Replicates should reflect the biological unit being compared, not simply multiple wells from one culture. Donor, line, clone, independent differentiation, passage, and batch can all matter. We map these factors before deciding how organoids are allocated to assays.
Can model development include gene editing?
Gene modification can be evaluated as a custom module. The appropriate design depends on the target, editing strategy, delivery method, clone requirements, genotype confirmation, and whether the modification affects organoid formation. It is not assumed that every edit or model combination is feasible.
Can the same organoid batch be used for sequencing, histology, and functional assays?
Sometimes, but each method may require a different material state or preparation. We plan sample allocation early and retain batch and passage identifiers so results can be compared. Additional expansion or independently prepared material may be necessary.
What information should I provide for an initial review?
Provide the research question, intended organ or disease context, species and source material, available controls, current culture or stem-cell information, target modification if any, planned downstream assays, desired delivery format, and relevant timing or shipping constraints.
Case Study: Building and Characterizing an Adenoma Organoid Biobank
Source. Luo and colleagues reported an independent 2023 study in BMC Medicine that established a patient-derived high-risk colorectal adenoma organoid biobank and used the models for molecular characterization and research-stage screening.
Background. The study required an expandable in vitro system that represented adenoma biology while providing enough material for repeat characterization and compound experiments. The researchers therefore treated culture establishment, purity, model documentation, and downstream use as connected tasks.
Methods. Organoids were derived from collected adenoma material and evaluated across culture conditions. The team documented morphology and growth, examined selected lineage and stemness markers, and compared transcriptomic and genetic characteristics with source material. Established cultures were expanded into a living biobank before downstream screening.
Results. The reported biobank contained 37 organoid lines derived from 33 individuals. The study showed that selected histological, cellular, genetic, and molecular characteristics of the source adenomas were represented in the organoid collection. The work also demonstrated how an established bank could support a standardized downstream experimental workflow.
Conclusion. The case illustrates why model development should not end with visible three-dimensional growth. Culture conditions, traceable source information, expansion, banking, and multiple levels of characterization together determine whether a model is ready for a defined research use. It does not establish a universal success rate or guarantee that another tissue type will behave the same way.
Independent research figure from Luo et al. (2023), BMC Medicine, https://doi.org/10.1186/s12916-023-03034-y. © The Author(s) 2023; reused under the Creative Commons Attribution 4.0 International License. The image was resized for legibility.
References:
- Ahn S-J, Lee S, Kwon D, et al. Essential Guidelines for Manufacturing and Application of Organoids. International Journal of Stem Cells. 2024;17(2):102-112. https://doi.org/10.15283/ijsc24047
- Luo Z, Wang B, Luo F, et al. Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening. BMC Medicine. 2023;21:336. https://doi.org/10.1186/s12916-023-03034-y
- Xu X, Kumari R, Zhou J, et al. A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology. PLOS ONE. 2023;18(1):e0279821. https://doi.org/10.1371/journal.pone.0279821
- Prondzynski M, Berkson P, Trembley MA, et al. Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems. Nature Communications. 2024;15:5929. https://doi.org/10.1038/s41467-024-50224-0
- Phipson B, Er PX, Combes AN, et al. Evaluation of variability in human kidney organoids. Nature Methods. 2019;16(1):79-87. https://doi.org/10.1038/s41592-018-0253-2
- Pleguezuelos-Manzano C, Puschhof J, van den Brink S, et al. Establishment and Culture of Human Intestinal Organoids Derived from Adult Stem Cells. Current Protocols in Immunology. 2020;130(1):e106. https://doi.org/10.1002/cpim.106